Ozanimod (RPC1063) is a potent sphingosine‐1‐phosphate receptor‐1 (S1P ₁ ) and receptor‐5 (S1P ₅ ) agonist with autoimmune disease‐modifying activity

Abstract

S1P receptor selectivity, favourable PK properties and efficacy in three distinct disease models supports the clinical development of RPC1063 for the treatment of relapsing multiple sclerosis and inflammatory bowel disease, differentiates RPC1063 from other S1P receptor agonists, and could result in improved safety outcomes in the clinic.